Nivolumab: beside a new treatment under test
581 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 6. Open to participants first (106), then studies with results posted, then the rest; newest registration first within each.
- A Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)Not yet recruitingNCT07935928Phase 2/3How we knowReport a problem
- STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic CarcinomaNot yet recruitingNCT07902921Phase 1/2How we knowReport a problem
- Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell CarcinomaNot yet recruitingNCT07896811Phase 2How we knowReport a problem
- Neoadjuvant RP2 + Nivolumab in Patients With MelanomaNot yet recruitingNCT07862530Phase 2How we knowReport a problem
- A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)Not yet recruitingNCT07848295Phase 1How we knowReport a problem
- A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal AdenocarcinomaNot yet recruitingNCT07818070Phase 3How we knowReport a problem
- A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07818018Phase 1/2How we knowReport a problem
- iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable MelanomaNot yet recruitingNCT07815574Phase 3How we knowReport a problem
- A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory LymphomaNot yet recruitingNCT07791615Phase 2How we knowReport a problem
- Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLCRecruitingNCT07718243Phase 1/2How we knowReport a problem
- Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMDRecruitingNCT07694986Phase 2How we knowReport a problem
- Axelopran and Nivolumab in PD-1-Refractory Metastatic MelanomaRecruitingNCT07631325Phase 1/2How we knowReport a problem
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationNCT07620574Phase 3How we knowReport a problem
- A 2-part Phase 1/2 Open-label Trial on ODM-212RecruitingNCT07563738Phase 1/2How we knowReport a problem
- A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerRecruitingNCT07532902Phase 1How we knowReport a problem
- Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell CarcinomaRecruitingNCT07529873Phase 2How we knowReport a problem
- Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal CancerRecruitingNCT07527858Phase 2How we knowReport a problem
- VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingNCT07510334Phase 2How we knowReport a problem
- Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCCNot yet recruitingNCT07494435Phase 2How we knowReport a problem
- Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)RecruitingNCT07432295Phase 2How we knowReport a problem
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2RecruitingNCT07431281Phase 3How we knowReport a problem
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)RecruitingNCT07430202Phase 1How we knowReport a problem
- A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)RecruitingNCT07401875Phase 1How we knowReport a problem
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingNCT07383441Phase 3How we knowReport a problem
- A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid TumorsRecruitingNCT07376707Phase 1How we knowReport a problem
- Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid TumorsRecruitingNCT07334119Phase 1How we knowReport a problem
- COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal CancerRecruitingNCT07328087Early Phase 1How we knowReport a problem
- Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)RecruitingNCT07319195Early Phase 1How we knowReport a problem
- Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesRecruitingNCT07276373Phase 1/2How we knowReport a problem
- Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLCRecruitingNCT07246863Phase 2How we knowReport a problem
- BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaRecruitingNCT07226856Phase 2How we knowReport a problem
- Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureRecruitingNCT07219459Phase 2How we knowReport a problem
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Phase 1How we knowReport a problem
- Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerRecruitingNCT07128680Phase 1How we knowReport a problem
- Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPCRecruitingNCT07090148Phase 1How we knowReport a problem
- A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.RecruitingNCT07017816Early Phase 1How we knowReport a problem
- Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial CarcinomaRecruitingNCT06983210Phase 2How we knowReport a problem
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal CancerRecruitingNCT06948448Phase 2How we knowReport a problem
- NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic CancerRecruitingNCT06941857Phase 2How we knowReport a problem
- SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)RecruitingNCT06889493Phase 1How we knowReport a problem
- Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialRecruitingNCT06866262Phase 1/2How we knowReport a problem
- Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCRecruitingNCT06863311Phase 2How we knowReport a problem
- Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT06841679Phase 2/3How we knowReport a problem
- A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular CarcinomaNot yet recruitingNCT06841185Phase 3How we knowReport a problem
- Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable MetastasisRecruitingNCT06794229Phase 2How we knowReport a problem
- A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsRecruitingNCT06764771Phase 1How we knowReport a problem
- A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).RecruitingNCT06646276Phase 3How we knowReport a problem
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsRecruitingNCT06618287Phase 1/2How we knowReport a problem
- Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney CancerRecruitingNCT06601296Phase 2How we knowReport a problem
- A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaRecruitingNCT06581406Phase 2/3How we knowReport a problem
- Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerRecruitingNCT06495125Phase 2How we knowReport a problem
- Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerRecruitingNCT06463665Phase 2How we knowReport a problem
- EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.RecruitingNCT06448572Phase 1/2How we knowReport a problem
- The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer PatientsRecruitingNCT06428422Not applicableHow we knowReport a problem
- CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerRecruitingNCT06399419Phase 1How we knowReport a problem
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyRecruitingNCT06362369Phase 1/2How we knowReport a problem
- VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]RecruitingNCT06264180Phase 3How we knowReport a problem
- First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric CancerRecruitingNCT06253611Phase 2How we knowReport a problem
- IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)RecruitingNCT06112314Phase 3How we knowReport a problem
- A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid TumorsRecruitingNCT06063681Phase 1How we knowReport a problem
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisRecruitingNCT06047379Phase 1/2How we knowReport a problem
- Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric CancerRecruitingNCT06008925Phase 1/2How we knowReport a problem
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingNCT05934331Phase 2How we knowReport a problem
- FOG-001 in Locally Advanced or Metastatic Solid TumorsRecruitingNCT05919264Phase 1/2How we knowReport a problem
- Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid TumorsRecruitingNCT05901285Phase 1How we knowReport a problem
- Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck CancerRecruitingNCT05838729Phase 1/2How we knowReport a problem
- Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint InhibitorsRecruitingNCT05834413Not applicableHow we knowReport a problem
- The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint InhibitorsRecruitingNCT05821751Not applicableHow we knowReport a problem
- Neoantigen Derived DCs as Cancer TreatmentRecruitingNCT05767684Phase 1How we knowReport a problem
- Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCRecruitingNCT05681780Phase 1How we knowReport a problem
- Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCRecruitingNCT05663710Phase 1/2How we knowReport a problem
- MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced MelanomaRecruitingNCT05655312Phase 1/2How we knowReport a problem
- Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint InhibitorsRecruitingNCT05629546Phase 1How we knowReport a problem
- Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid TumorsRecruitingNCT05608148Phase 1How we knowReport a problem
- A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsRecruitingNCT05584670Phase 1/2How we knowReport a problem
- FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 TherapyRecruitingNCT05533983Not applicableHow we knowReport a problem
- Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsRecruitingNCT05533697Phase 1/2How we knowReport a problem
- Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in MelanomaRecruitingNCT05498792Early Phase 1How we knowReport a problem
- Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive CarcinomaNot yet recruitingNCT05461235Phase 2How we knowReport a problem
- A Study of TRK-950 in Patients With Advanced Solid TumorsRecruitingNCT05423262Phase 1/2How we knowReport a problem
- Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsRecruitingNCT05317858Phase 3How we knowReport a problem
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerRecruitingNCT05267626Phase 1/2How we knowReport a problem
- Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid TumorsRecruitingNCT05266612Phase 1How we knowReport a problem
- CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular CarcinomaRecruitingNCT05257590Phase 2How we knowReport a problem
- KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLCRecruitingNCT05254184Phase 1How we knowReport a problem
- PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05234307Phase 1How we knowReport a problem
- An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic CholangiocarcinomaRecruitingNCT05223816Phase 2How we knowReport a problem
- CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal CancerRecruitingNCT05187182Phase 1How we knowReport a problem
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsRecruitingNCT05176483Phase 1How we knowReport a problem
- Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic CancerRecruitingNCT05162118Phase 1/2How we knowReport a problem
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerRecruitingNCT05098210Phase 1How we knowReport a problem
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsRecruitingNCT05076760Phase 1How we knowReport a problem
- HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced SarcomaRecruitingNCT04995003Phase 1How we knowReport a problem
- Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICIRecruitingNCT04954599Phase 1/2How we knowReport a problem
- Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AMLRecruitingNCT04913922Phase 2How we knowReport a problem
- Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRCRecruitingNCT04912765Phase 2How we knowReport a problem
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Phase 1How we knowReport a problem
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsRecruitingNCT04895709Phase 1/2How we knowReport a problem
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV MelanomaRecruitingNCT04697576Phase 1How we knowReport a problem
- Study to Evaluate VT3989 in Patients With Metastatic Solid TumorsRecruitingNCT04665206Phase 1/2How we knowReport a problem